Both NeuroMove and TruWave devices have previously received the FDA’s clearance for marketing in the US.
NeuroMove is marketed for stroke and spinal cord injury rehabilitation and TruWave is an electrotherapy device.
Thomas Sandgaard, CEO of Zynex, said: “The CE marking allows us to sell these products in the EU and we also anticipate it will help the process of regulatory approval in many other countries outside of Europe.”